Bionano Genomics, Inc. financials

BNGO CIK 0001411690

Source: EDGAR filings · Built 2026-06-19T02:04:27Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -38.31M
EBITDA -23.81M -89.96M -201.54M -122.08M -73.75M -37.07M
Working Capital 22.44M 2.15M 40.09M 121.41M 250.57M 37.84M
Net Debt 3.92M -2.24M -8.34M 6.58M -13.88M -22.12M
Gross Margin 46.25% 1.23% 26.49% 21.38% 21.55% 32.61%
Operating Margin -116.95% -337.87% -595.98% -473.70% -428.79% -453.38%
Net Margin -92.59% -363.98% -643.74% -476.93% -402.84% -483.43%
Return on Equity (ROE) -59.42% -316.66% -241.78% -53.17% -21.49% -117.17%
Return on Assets (ROA) -35.87% -146.10% -108.44% -43.12% -19.21% -68.00%
Current Ratio 1.98× 1.06× 1.40× 4.38× 12.47× 5.23×
Debt-to-Equity 0.16× 0.20× 0.10× 0.05× 0.03× 0.47×
Effective Tax Rate -0.25% -0.03% -0.03% -1.44% 7.32% -0.07%
Cash Conversion Ratio 0.62× 0.62× 0.54× 0.94× 0.99× 0.93×
Accruals Ratio -0.14× -0.56× -0.50× -0.03× -0.00× -0.05×
SBC % of Revenue 15.90% 31.64% 42.03% 80.63% 54.05% 18.28%
Free Cash Flow Per Share $-0.37

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 28.51M 30.78M 36.12M 27.80M 17.98M 8.50M
Cost of Goods and Services Sold 15.32M 30.40M 26.55M 21.86M 14.11M 5.73M
Research and Development Expense 11.37M 24.80M 54.03M 49.05M 22.48M 10.26M
Selling, General and Administrative Expense 35.15M 51.85M 92.76M 88.60M 58.49M 31.07M
Operating Income (Loss) -33.34M -103.98M -215.25M -131.70M -77.10M -38.55M
Income Tax Expense (Benefit) 67.00K 33.00K 62.00K 1.88M -5.72M 29.00K
Net Income (Loss) Attributable to Parent -26.39M -112.02M -232.49M -132.60M -72.44M -41.11M
Earnings Per Share, Basic $-4.85 $-88.13 $-408.60 $-4.58 $-0.26
Weighted Average Number of Shares Outstanding, Basic 5.45M 1.27M 569,000 28.92M 276.78M
Earnings Per Share, Diluted $-4.85 $-88.13 $-408.60 $-4.58 $-0.26
Weighted Average Number of Shares Outstanding, Diluted 5.45M 1.27M 569,000 28.92M 276.78M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 2.99M 9.17M 17.95M 5.09M 24.57M 38.45M
Assets, Current 45.39M 39.49M 140.12M 157.30M 272.41M 46.79M
Assets 73.58M 76.67M 214.40M 307.50M 377.10M 60.45M
Long-term Debt 16.33M
Liabilities, Current 22.94M 37.34M 100.03M 35.88M 21.84M 8.95M
Long-term Debt, Excluding Current Maturities 0 16.32M
Liabilities 29.16M 41.30M 118.25M 58.10M 39.98M 25.37M
Stockholders' Equity Attributable to Parent 44.42M 35.38M 96.16M 249.40M 337.12M 35.08M
Common Stock, Shares, Outstanding 10.74M 1.87M 762,533 29.72M 289.60M 189.95M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -16.34M -68.92M -125.18M -124.82M -71.93M -38.31M
Payments to Acquire Property, Plant, and Equipment 0
Net Cash Provided by (Used in) Investing Activities -12.75M 73.84M 24.16M 82.77M -278.06M -2.45M
Net Cash Provided by (Used in) Financing Activities 24.04M -13.69M 113.81M 23.01M 336.11M 61.90M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (BNGO CIK 0001411690), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NN

NEXTNAV INC.

WEX

WEX Inc.

ELOXD

ELOXX PHARMACEUTICALS, INC.